+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Varicella Live Vaccine Market by Product, Application, and Provider: Global Opportunity Analysis and Industry Forecast, 2018-2026

  • ID: 4989438
  • Report
  • October 2019
  • Region: Global
  • 178 pages
  • Allied Analytics LLP
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Bio-Med Pvt. Limited
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • MORE
The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026.
Varicella live vaccines contain an attenuated form of the varicella zoster virus. These vaccines help build immunity against varicella zoster virus as the infection can cause serious diseases such as chicken pox and herpes zoster. Immunization against these diseases is necessary as chicken pox can lead to serious complications such as bacterial infections of the skin and soft tissues in children. Moreover, herpes zoster is another painful condition that is caused by the reactivation of the varicella zoster virus after primary infection. Therefore, immunization with varicella live vaccine serves as an effective method for prevention of these diseases. These vaccines are mainly of two types such as monovalent and combination. The monovalent vaccines contain a single strain of a single antigen such as varicella live vaccines, contain weakened strain of varicella zoster virus. However, the combination varicella vaccines contain multiple strains of infectious agents.

The factors that boost the growth of the varicella live vaccine market include a surge in immunization programs across the globe. Moreover, rise in awareness related to the use of varicella live vaccines and a surge in adoption of varicella vaccination worldwide also fuel the growth of the varicella live vaccine market. However, high monetary inputs associated with the production of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

The global varicella live vaccine market is segmented based on product, application, provider, and region. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization. On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS
  • This report entails a detailed quantitative analysis along with the current global varicella live vaccine market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
KEY MARKET SEGMENTS

By Product
  • Monovalent Varicella Vaccine
  • Combination Varicella Vaccine
By Application
  • Chickenpox immunization
  • Herpes Zoster Immunization
  • Mumps, Measles, Rubella and Varicella (MMRV) Immunization
By Provider
  • Public Provider
  • Private Provider
By Region

North America
  • U.S.
  • Canada
  • Mexico
Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
List of key players profiled in the report:
  • Bio-Med Pvt. Limited
  • Changchun BCHT Biotechnology Co. Ltd.
  • Emcure Pharmaceuticals Limited
  • GlaxoSmithKline plc
  • Green Cross Holdings (GC Pharma)
  • Merck & Co. Inc.
  • Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
  • Novo Medi Sciences Pvt. Ltd.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
  • VHB Life Sciences
  • Wockhardt Ltd.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bio-Med Pvt. Limited
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • MORE
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models

Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective

Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. Porter'S Five Forces Analysis
3.3.1. Bargaining Power of Buyers
3.3.2. Bargaining Power of Suppliers
3.3.3. Thereat of New Entrants
3.3.4. Threat of Substitutes
3.3.5. Intensity of Competitive Rivalry
3.4. Top Player Positioning, 2018
3.5. Market Dynamics
3.5.1. Drivers
3.5.1.1. Surge In Immunization Programs Across The Globe
3.5.1.2. Rise In Awareness Regarding Use of Varicella Live Vaccines
3.5.1.3. Increase In Adoption of Varicella Live Vaccines
3.5.2. Restraint
3.5.2.1. High Monetary Inputs Associated With The Production
3.5.3. Opportunity
3.5.3.1. High Growth Potential In Emerging Economies
3.5.4. Impact Analysis

Chapter 4: Varicella Live Vaccine Market, By Product
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Monovalent Varicella Vaccine
4.2.1. Key Market Trends And Growth Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis, By Country
4.3. Combination Varicella Vaccine
4.3.1. Key Market Trends And Growth Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country

Chapter 5: Varicella Live Vaccine Market, By Application
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Chickenpox Immunization
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis, By Country
5.3. Herpes Zoster Immunization
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis, By Country
5.4. Mumps, Measles, Rubella & Varicella (Mmrv) Immunization
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis, By Country

Chapter 6: Varicella Vaccine Market, By Provider
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Public
6.2.1. Market Size And Forecast, By Region
6.2.2. Market Analysis, By Country
6.3. Private
6.3.1. Market Size And Forecast, By Region
6.3.2. Market Analysis, By Country

Chapter 7: Varicella Live Vaccine Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends And Opportunities
7.2.2. Market Analysis By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Market Size And Forecast, By Product
7.2.2.1.2. U.S. Market Size And Forecast, By Application
7.2.2.1.3. U.S. Market Size And Forecast, By Provider
7.2.2.2. Canada
7.2.2.2.1. Canada Market Size And Forecast, By Product
7.2.2.2.2. Canada Market Size And Forecast, By Application
7.2.2.2.3. Canada Market Size And Forecast, By Provider
7.2.2.3. Mexico
7.2.2.3.1. Mexico Market Size And Forecast, By Product
7.2.2.3.2. Mexico Market Size And Forecast, By Application
7.2.2.3.3. Mexico Market Size And Forecast, By Provider
7.2.3. North America Market Size And Forecast, By Product
7.2.4. North America Market Size And Forecast, By Application
7.2.5. North America Market Size And Forecast, By Provider
7.3. Europe
7.3.1. Key Market Trends And Opportunities
7.3.2. Market Analysis By Country
7.3.2.1. Germany
7.3.2.1.1. Germany Market Size And Forecast, By Product
7.3.2.1.2. Germany Market Size And Forecast, By Application
7.3.2.1.3. Germany Market Size And Forecast, By Provider
7.3.2.2. France
7.3.2.2.1. France Market Size And Forecast, By Product
7.3.2.2.2. France Market Size And Forecast, By Application
7.3.2.2.3. France Market Size And Forecast, By Provider
7.3.2.3. UK
7.3.2.3.1. UK Market Size And Forecast, By Product
7.3.2.3.2. UK Market Size And Forecast, By Application
7.3.2.3.3. UK Market Size And Forecast, By Provider
7.3.2.4. Italy
7.3.2.4.1. Italy Market Size And Forecast, By Product
7.3.2.4.2. Italy Market Size And Forecast, By Application
7.3.2.4.3. Italy Market Size And Forecast, By Provider
7.3.2.5. Spain
7.3.2.5.1. Spain Market Size And Forecast, By Product
7.3.2.5.2. Spain Market Size And Forecast, By Application
7.3.2.5.3. Spain Market Size And Forecast, By Provider
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Market Size And Forecast, By Product
7.3.2.6.2. Rest of Europe Market Size And Forecast, By Application
7.3.2.6.3. Rest of Europe Market Size And Forecast, By Provider
7.3.3. Europe Market Size And Forecast, By Product
7.3.4. Europe Market Size And Forecast, By Application
7.3.5. Europe Market Size And Forecast, By Provider
7.4. Asia-Pacific
7.4.1. Key Market Trends And Opportunities
7.4.2. Market Analysis By Country
7.4.2.1. Japan
7.4.2.1.1. Japan Market Size And Forecast, By Product
7.4.2.1.2. Japan Market Size And Forecast, By Application
7.4.2.1.3. Japan Market Size And Forecast, By Provider
7.4.2.2. China
7.4.2.2.1. China Market Size And Forecast, By Product
7.4.2.2.2. China Market Size And Forecast, By Application
7.4.2.2.3. China Market Size And Forecast, By Provider
7.4.2.3. Australia
7.4.2.3.1. Australia Market Size And Forecast, By Product
7.4.2.3.2. Australia Market Size And Forecast, By Application
7.4.2.3.3. Australia Market Size And Forecast, By Provider
7.4.2.4. India
7.4.2.4.1. India Market Size And Forecast, By Product
7.4.2.4.2. India Market Size And Forecast, By Application
7.4.2.4.3. India Market Size And Forecast, By Provider
7.4.2.5. South Korea
7.4.2.5.1. South Korea Market Size And Forecast, By Product
7.4.2.5.2. South Korea Market Size And Forecast, By Application
7.4.2.5.3. South Korea Market Size And Forecast, By Provider
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific Market Size And Forecast, By Product
7.4.2.6.2. Rest of Asia-Pacific Market Size And Forecast, By Application
7.4.2.6.3. Rest of Asia-Pacific Market Size And Forecast, By Provider
7.4.3. Asia-Pacific Market Size And Forecast, By Product
7.4.4. Asia-Pacific Market Size And Forecast, By Application
7.4.5. Asia-Pacific Market Size And Forecast, By Provider
7.5. LAMEA
7.5.1. Key Market Trends And Opportunities
7.5.2. Market Analysis By Country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Market Size And Forecast, By Product
7.5.2.1.2. Brazil Market Size And Forecast, By Application
7.5.2.1.3. Brazil Market Size And Forecast, By Provider
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Market Size And Forecast, By Product
7.5.2.2.2. Saudi Arabia Market Size And Forecast, By Application
7.5.2.2.3. Saudi Arabia Market Size And Forecast, By Provider
7.5.2.3. South Africa
7.5.2.3.1. South Africa Market Size And Forecast, By Product
7.5.2.3.2. South Africa Market Size And Forecast, By Application
7.5.2.3.3. South Africa Market Size And Forecast, By Provider
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA Market Size And Forecast, By Product
7.5.2.4.2. Rest of LAMEA Market Size And Forecast, By Application
7.5.2.4.3. Rest of LAMEA Market Size And Forecast, By Provider
7.5.3. LAMEA Market Size And Forecast, By Product
7.5.4. LAMEA Market Size And Forecast, By Application
7.5.5. LAMEA Market Size And Forecast, By Provider

Chapter 8: Company Profiles
8.1. Bio-Med Pvt. Limited
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Product Portfolio
8.1.4. Key Strategic Moves And Developments
8.2. Changchun Bcht Biotechnology Co. Ltd.
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Product Portfolio
8.3. Emcure Pharmaceuticals Limited (Zuventus Healthcare Ltd.)
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Product Portfolio
8.4. Glaxosmithkline Plc
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.5. Green Cross Holdings (Gc Pharma)
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Product Portfolio
8.5.4. Business Performance
8.6. Merck & Co. Inc.
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.6.6. Key Strategic Moves And Developments
8.7. Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.7.6. Key Strategic Moves And Developments
8.8. Novo Medi Sciences Pvt. Ltd.
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Product Portfolio
8.9. Sanofi
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.9.5. Business Performance
8.10. Takeda Pharmaceutical Company Limited
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Bio-Med Pvt. Limited
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • MORE
According to the report titled,'Varicella Live Vaccine Market by Product, Application, and Provider: Global Opportunity Analysis and Industry Forecast, 2018-2026,' the global varicella live vaccine market was valued at $2.71 billion in 2018, and is expected to reach $4.22 billion by 2026, registering a CAGR of 5.7% from 2019 to 2026.

Viral infections can be prevented by immunization and therefore, immunization is crucial. Varicella zoster is a virus that causes diseases such as chicken pox and herpes zoster. However, these infectious diseases can be prevented by the use of varicella live vaccines. Varicella live vaccines are administered to both children and adults in a pattern of two doses to ensure complete immunization. These vaccines contain a weakened form of varicella zoster virus that is effective in creating immunity against the same virus. There are two different types of varicella live vaccines such as monovalent and combination varicella vaccines.

Rise in immunization programs worldwide is the major factor that boost the growth of the varicella live vaccine market. In addition, factors such as surge in awareness related to the use of varicella live vaccines and increase in adoption of varicella vaccination across the globe fuel the growth of the varicella live vaccine market. However, high monetary inputs associated with manufacture of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period.

The global varicella live vaccine market is segmented based on product, application, and provider. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella and varicella (MMRV) immunization.

On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Based on product, the monovalent varicella vaccine segment acquired the major share of the varicella live vaccine market and is expected to experience rapid growth during the forecast period as these vaccines exhibit lesser chances of inducing febrile seizures in children as compared to combination vaccines. Moreover, easy availability and presence of large number of products is another reason that boosts the growth of the monovalent varicella vaccine market.

Based on application, chicken pox immunization acquired the largest share of the varicella live vaccine market owing to vaccination employed with an initial aim of building immunity against chicken pox. Herpes zoster segment is expected to grow at the fastest rate during the forecast period owing to surge in geriatric population worldwide and rise in awareness about the use of varicella live vaccines for herpes zoster.

On the basis of region, North America acquired a major share owing to easy availability of varicella live vaccines, presence of skilled healthcare experts, and presence of major key players that offer varicella live vaccines. Asia-Pacific is expected to grow at the fastest rate during the forecast period due to surge in awareness related to importance of immunization and rise in disposable income.

The developing economies offer lucrative opportunities for varicella live vaccine providers to expand their business. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and others.

Key Findings of The Varicella Live Vaccine Market:
Monovalent varicella vaccine occupied two-thirds share of the global varicella live vaccine market in 2018
The herpes zoster segment is anticipated to grow with the highest CAGR throughout the forecast period
The private segment accounted for two-third share of the market in 2018
Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA
Note: Product cover images may vary from those shown
5 of 5
  • Bio-Med Pvt. Limited
  • Changchun BCHT Biotechnology Co. Ltd.
  • Emcure Pharmaceuticals Limited
  • GlaxoSmithKline plc
  • Green Cross Holdings (GC Pharma)
  • Merck & Co. Inc.
  • Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporat
Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll